Oppenheimer Maintains Outperform on Apellis Pharmaceuticals, Raises Price Target to $79

Apellis Pharmaceuticals +0.21%

Apellis Pharmaceuticals

APLS

33.21

+0.21%

Oppenheimer analyst Justin Kim maintains Apellis Pharmaceuticals (NASDAQ: APLS) with a Outperform and raises the price target from $75 to $79.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via